ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0849

Herpes Zoster Events with Anifrolumab in Patients with Active SLE: An Integrated Analysis of Phase 2 and Phase 3 Trials

Joan Merrill1, Kenneth Kalunian2, Richard Furie3, Kevin Winthrop4, Patricia Primakov5, Lilia Pineda6, Gabriel Abreu7 and Raj Tummala6, 1Oklahoma Medical Research Foundation, Oklahoma City, 2School of Health Sciences, University of California, La Jolla, 3Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 4Oregon Health & Science University, Portland, OR, 5BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 6BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, 7BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

Meeting: ACR Convergence 2020

Keywords: Biologicals, clinical trial, Dermatology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Saturday, November 7, 2020

Session Title: SLE – Treatment Poster I

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: In the phase 2 MUSE and phase 3 TULIP-1 and TULIP-2 trials, treatment with anifrolumab, a monoclonal antibody to the type I interferon receptor, was associated with clinical benefit in patients (pts) with SLE.1–3 In all 3 trials, herpes zoster (HZ) was observed more frequently with anifrolumab vs placebo. We conducted an integrated analysis to characterize the frequency and nature of HZ events with anifrolumab across the MUSE and TULIP trials.

Methods: MUSE, TULIP-1, and TULIP-2 were randomized, double-blind, 52-wk trials that evaluated anifrolumab 300 mg (IV Q4W for 48 wks) or placebo in pts with moderately to severely active SLE despite SOC.1–3 MUSE also included a 1000-mg treatment arm, and TULIP-1 included a 150-mg treatment arm; these pts were analyzed separately. We assessed HZ AE incidence, severity, intensity, discontinuation, and time to onset.

Results: In pooled data from MUSE, TULIP-1, and TULIP-2, 459 pts received ≥1 dose of anifrolumab 300 mg and 466 received ≥1 dose of placebo. In addition, 93 pts received anifrolumab 150 mg in TULIP-1 and 105 received 1000 mg in MUSE. HZ occurred in 5.4% (n=5), 6.1% (n=28), and 8.6% (n=9) of pts in the anifrolumab 150-mg, 300-mg, and 1000-mg groups, respectively, and in 1.3% (n=6) of the pooled placebo group (Table 1). Forty-four pts had HZ AEs that were mild or moderate, and 4 had events that were severe (anifrolumab 300 mg, n=2; 1000 mg, n=2). Three pts had serious AEs of HZ (anifrolumab 300 mg, n=2; 1000 mg, n=1). Of the 48 pts with HZ AEs, all but 4 continued in the study and all AEs leading to discontinuation were nonserious and moderate (anifrolumab 150 mg, n=1; 300 mg, n=2; 1000 mg, n=1). In pooled data available from TULIP-1 and -2, all HZ AEs with anifrolumab 300 mg were cutaneous (21 localized, unilateral; 2 disseminated, unilateral); all 5 HZ AEs with placebo were localized cutaneous. HZ resolved in all cases in MUSE and TULIP; all pts in the anifrolumab group and 4 of 6 pts in the placebo group received antiviral treatment. Using pooled TULIP data, no pattern of HZ event frequency was identified in protocol-defined subgroups. Pts using immunosuppressants (IS; n=349) had a difference in the rate of HZ between anifrolumab vs placebo groups of 8.1% (CI 2.6, 13.7) and those without IS use (n=376) had a difference of 2.2% (CI –1.8, 6.2) (Figure 1). Time to first onset of HZ was marginally shorter in the anifrolumab 300-mg vs placebo group (Figure 2).

Conclusion: In MUSE and TULIP trials, there appears to be an increased risk of HZ with anifrolumab vs placebo. HZ event characteristics, including duration and severity, were comparable between treatment groups, and most HZ events were mild to moderate, cutaneous, and resolved without discontinuation of study drug.

References

  1. Furie R. Arthritis Rheumatol. 2017;69:376–86.
  2. Furie R. Lancet Rheumatol. 2019;1:e208–19.
  3. Morand EF. N Engl J Med. 2020;382:211–21.

Writing assistance by Angela Cimmino, PharmD (JK Associates Inc., a Fishawack Health Company).

This study was sponsored by AstraZeneca.

Table 1. Herpes Zoster Events During Treatment With Anifrolumab 300 mg vs Placebo in Pooled MUSE, TULIP-1, and TULIP-2 Data, 150 mg vs Placebo in TULIP-1, and 1000 mg vs Placebo in MUSE

Figure 1. Adjusted Difference in Cumulative Proportions of Patients With Herpes Zoster Events With Anifrolumab 300 mg vs Placebo in Pooled TULIP-1 and TULIP-2 Data

Figure 2. Time to First Onset of Herpes Zoster During Treatment With Anifrolumab 300 mg vs Placebo in Pooled MUSE, TULIP-1, and TULIP-2 Data


Disclosure: J. Merrill, Bristol Myers Squibb, 2, 5, GlaxoSmithKline, 2, 5, AstraZeneca, 5, AbbVie, 5, Amgen, 5, Aurinia, 5, EMD Serono, 5, Remegen, 5, Janssen, 5, Provention, 5, UCB, 5; K. Kalunian, AstraZeneca, 5; R. Furie, AstraZeneca/MedImmune, 2, 5; K. Winthrop, Pfizer, 2, 5, UCB, 2, 5, Abbvie, 2, 5, Galapagos, 2, 5, Gilead, 2, 5, Roche, 2, 5, Bristol-Myers Squibb, 2, 5, Eli Lilly, 2, 5, GlaxoSmithKline, 5; P. Primakov, AstraZeneca, 1, 3; L. Pineda, AstraZeneca, 3; G. Abreu, AstraZeneca, 3; R. Tummala, AstraZeneca, 3.

To cite this abstract in AMA style:

Merrill J, Kalunian K, Furie R, Winthrop K, Primakov P, Pineda L, Abreu G, Tummala R. Herpes Zoster Events with Anifrolumab in Patients with Active SLE: An Integrated Analysis of Phase 2 and Phase 3 Trials [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/herpes-zoster-events-with-anifrolumab-in-patients-with-active-sle-an-integrated-analysis-of-phase-2-and-phase-3-trials/. Accessed March 3, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/herpes-zoster-events-with-anifrolumab-in-patients-with-active-sle-an-integrated-analysis-of-phase-2-and-phase-3-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.